UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number 001-41923
EUPRAXIA PHARMACEUTICALS INC.
(Translation of registrant’s name into English)
201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☐ Form 40-F ☒
INCORPORATION BY REFERENCE
Exhibits 99.1
and 99.2 of this Form 6-K are incorporated by reference into the registrant’s Registration Statement on Form F-10 (File
No. 333-276586) and the registrant’s Registration Statement on Form S-8 (File No. 333-278534).
DOCUMENTS INCLUDED AS PART OF THIS REPORT
|
|
|
| Exhibit |
|
|
|
|
| 99.1 |
|
Consolidated Financial Statements for the three and nine months ended September 30, 2025. |
|
|
| 99.2 |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2025. |
|
|
| 99.3 |
|
Press Release, dated November 4, 2025. |
|
|
| 99.4 |
|
Form 52-109F2 Certification of Interim Filings by CEO. |
|
|
| 99.5 |
|
Form 52-109F2 Certification of Interim Filings by CFO. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Eupraxia Pharmaceuticals Inc. |
|
|
|
|
| Date: November 4, 2025 |
|
|
|
By: |
|
/s/ Alex Rothwell |
|
|
|
|
|
|
Name: Alex Rothwell |
|
|
|
|
|
|
Title: Chief Financial Officer |
